Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Enrique Grande(MD Anderson Cancer Center Madrid), Arash Rezazadeh Kalebasty(University of California, Irvine), Eiji Kikuchi(Keio University), Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), Jóse Ángel Arranz Arija(Hospital General Universitario Gregorio Marañón), Marina Mencinger(Institute of Oncology Ljubljana), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Darren Tayama, Aristotelis Bamias(National and Kapodistrian University of Athens), Xavier García del Muro(Institut Català d'Oncologia), Kouji Izumi(Kanazawa University Hospital), Se Hoon Park(Samsung Medical Center), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Ian D. Davis(Austin Health), Almut Mecke(Roche (Switzerland)), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Maria De Santis(Medical University of Vienna), Stefano Panni(Istituti Ospitalieri di Cremona), Dingwei Ye(Fudan University), Fabio A. Schutz(Beneficência Portuguesa de São Paulo), Sandrine Bernhard(Roche (United Kingdom)), Jian-Ri Li(Taichung Veterans General Hospital), AnnChristine Thåström, Mahmut Gümüş(Istanbul Medeniyet University)
Cited by 786
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k